Oncology Focus (Neuroendocrine Tumors)
Neuroendocrine Tumors
Key Facts
About Curium Pharma
Curium Pharma, founded in 2017 and headquartered in Paris, France, is a commercial-stage company and self-proclaimed global leader in nuclear medicine. It operates a fully integrated business model encompassing development, manufacturing, and global supply of a broad portfolio of over 50 diagnostic and therapeutic radiopharmaceuticals. With significant infrastructure including four manufacturing sites, 44 radiopharmacies, and a molybdenum processing plant, Curium serves over 6,000 customers in more than 60 countries. The company is executing a 2030 vision to solidify its position as an oncology-focused leader, expanding into key Asian markets and investing in new technologies, including artificial intelligence for image analysis.
View full company profileTherapeutic Areas
Other Neuroendocrine Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| LNTH-2501/EVG-001 (Ga-68 edotreotide) | Lantheus Medical Imaging | Regulatory Filing |
| Lutathera® | Novartis | Approved / Phase III |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| LNC1010 / LNC1014 | Lantheus Holdings | Phase 1 |
| CRN01941 | Crinetics Pharmaceuticals | Phase 1 |